ABSTRACT:
Apalutamide is a second-generation oral competitive androgen receptor inhibitor and nonsteroidal antiandrogen, formulated to treat prostate carcinoma by binding Explicitly to the ligand binding domain of the androgen receptor and negating the Impact of androgens. The principal objective is to establish, design, and validate a greenness UV spectrophotometric method, forced degradation studies, and infrared analysis for the assessment of Apalutamide in crude and tablet dosage forms. A precise and cost-efficient UV spectrophotometric method has been constructed using methanol and 0.01N potassium dihydrogen orthophosphate (80:20v/v). In comparison to a control sample, the absorbance of standard solutions comprising 100µg/mL of drug solution was measured at an absorption maximum of 241nm. The regression equation (y = 0.0212x - 0.1011) was derived based on a correlation coefficient of R² = 0.9995 and a linear dynamic range of 10.0–50.0µg/mL. There were fewer than 2.0% relative standard deviations (RSD) between and within replicate sets. The findings indicate that the LOQ is 0.3µg/mL and the LOD is 0.0941µg/mL. Success criteria established by the FDA demonstrated stress-limits that fell between 5% and 20% of the total proportion. To Gauge the environmental endurance Implication, three distinct methodologies were employed: the AGREE, the BAGI, and MoGAPI. The chromatographic procedure’s eco-conformity is evidenced by the AGREE metric of 0.79, MoGAPI score of 81 with eight green segments, and BAGI index of 77.5. All validation parameters were substantiated to be Confined to the Tenable limits in compliance with ICH guidelines. This approach may serve as a valuable analytical asset in pharmaceutical laboratories for quality control applications, ensuring the therapeutic integrity of Apalutamide-based pharmaceutical products.